BRIEF-Genentech says phase III study evaluating Gazyva did **t meet primary endpoint
 

BRIEF-Genentech says phase III study evaluating Gazyva did **t meet primary endpoint
* Genentech provides update on phase III study of Gazyva inpeople with previously untreated diffuse large b-cell lymphomahttp://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...so:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...so:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/FGGAYLfS4IM